Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has gained more than 15% over the past month, mainly driven by the stock’s inclusion in the Russell 3000 index and strong Q1 2026 earnings. Wall Street expects more than 21% upside over the next 12-months making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts.

​During the fiscal Q1 2026 earnings, the company posted $21.1 million in revenue, surpassing the expectations of $9.78 million by a huge margin. Revenue for the quarter grew 1,523% year-over-year, driven by $20 million in development milestones from the Novo Nordisk licensing agreement for the LX9851 obesity program.

Moreover, liquidity also strengthened with a new $100 million loan facility from Hercules Capital, with an initial $55 million funded to support operations for at least the next 12 months. Management also highlighted that the progress for the SONATA-HCM Phase 3 trial remains strong and that the company plans to resubmit the ZYNQUISTA New Drug Application for type 1 diabetes by mid-2026.

​Last month, on May 11, Citi raised the price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a Buy rating on the shares.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on developing and commercializing therapies for human disease.

While we acknowledge the risk and potential of LXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1